Literature DB >> 3707626

A multicenter study of annual health service utilization and costs in rheumatoid arthritis.

D P Lubeck, P W Spitz, J F Fries, F Wolfe, D M Mitchell, S H Roth.   

Abstract

The economic impact of chronic illness has important implications for medical practice and health policy. To determine the yearly costs of illness for those who have rheumatoid arthritis, a detailed, self-administered questionnaire was developed. The questionnaire was completed by 940 patients. Direct costs (recorded as charges) include the average annual expenditures by all patients and third party payers for: hospital care ($913), physician costs ($206), other health professional visits ($71), medications ($436), laboratory tests ($217), radiographs ($116), assistive devices ($24), and nontraditional therapies ($22). The total annual medical costs per patient were $2,533. In a multivariate analysis that controlled for age, sex, education, and disease duration, the outpatient costs, inpatient costs, and total costs were all positively related to the Health Assessment Questionnaire Disability Index (P f less than 0.01) and global health (P f less than 0.01), but were not associated with self-reported pain.

Entities:  

Mesh:

Year:  1986        PMID: 3707626     DOI: 10.1002/art.1780290405

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  23 in total

Review 1.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

Authors:  Marco Barbieri; John B Wong; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Fibromyalgia and the Prediction of Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients.

Authors:  Hyein Kim; Jing Cui; Michelle Frits; Christine Iannaccone; Jonathan Coblyn; Nancy A Shadick; Michael E Weinblatt; Yvonne C Lee
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11-14       Impact factor: 4.794

Review 4.  Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  H A Wynne; M Campbell
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

5.  The present and future of comprehensive outcome measures for rheumatic diseases.

Authors:  P W Spitz; J F Fries
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

Review 6.  The costs of rheumatoid arthritis.

Authors:  S H Allaire; M J Prashker; R F Meenan
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 7.  A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.

Authors:  D P Lubeck
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.

Authors:  A Boonen; D van der Heijde; R Landewé; F Guillemin; M Rutten-van Mölken; M Dougados; H Mielants; K de Vlam; H van der Tempel; S Boesen; A Spoorenberg; H Schouten; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

9.  Determinants of direct costs in Dutch rheumatoid arthritis patients.

Authors:  S M M Verstappen; H Verkleij; J W J Bijlsma; E Buskens; A A Kruize; A H M Heurkens; M J Van Der Veen; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

10.  Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.

Authors:  D Huscher; S Merkesdal; K Thiele; H Zeidler; M Schneider; A Zink
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.